Advertisement

KLTO

Klotho Neurosciences, Inc.

Healthcare · USD

Set alert

Price alert · KLTO

All alert types
0.38 USD 0.00 0.00%
As of Mar 16, 2026 Extended hours 0.53 +40.13%
Bid
0.52 × 47
Ask
0.52 × 47
0.37 Day range 0.41
0.26 52-week range 13.10
YTD
+31.83%
1 year
+34.72%
Open
0.406
Prev close
0.381
Mkt cap
9.86M
Vol
95.00K
Avg vol
522.99K
EPS
-0.32
P/E
0.00
Div yield
0.00%
More statistics
Low
0.37
High
0.41
Forward P/E
0.00
Beta
0.06
Short ratio
0.34
Inst. own
11.42%
Dividend
0.00
Ex-div date
50-d avg
0.45094
200-d avg
3.47
1y target
0.00

2Y chart

Chart tools
Interval
KLTO two-year price chart0.111.062.012.963.91Aug 24Dec 24Apr 25Jul 25Nov 25Mar 26

Key statistics

Market cap
9.86M
Enterprise value
10.29M
Trailing P/E
0.00
Forward P/E
0.00
PEG ratio
0.00
Price / sales
0.00
Price / book
424.00
EPS (TTM)
0.00
Beta
0.06
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-168.17K
Total cash
845.34K
Total debt
3.90M
Return on equity
0.00%
Shares outstanding
23.26M
Short % of float
0.00%
50-day average
0.45094
200-day average
3.47

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
KLTO Revenue — quarterly 0
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025
KLTO Net income — quarterly -2.90M
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025
KLTO EPS — quarterly -0.05
2021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 2025

About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on KLTO — it syncs with the Stock Master app.

Insider holders

KLTO insider holders
InsiderRelationLatest transactionDateShares held
CHARDAN MONTEREY INVESTMENTS LLCBeneficial Owner of more than 10% of a Class of SecuritySaleJul 1, 20241,284,360

Institution ownership

KLTO institution ownership
Holder% heldSharesValueReported
Meteora Capital, LLC2.51%533,951226.40KSep 29, 2024
Morgan Stanley0.47%100,00042.40KSep 29, 2024
MMCAP International, Inc. SPC0.38%80,00033.92KSep 29, 2024
Geode Capital Management, LLC0.30%63,23426.81KSep 29, 2024
UBS Group AG0.07%15,3066.49KSep 29, 2024
Gabelli & Co. Investment Advisers, Inc.0.05%10,0004.24KSep 29, 2024

Fund ownership

KLTO fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.23%47,92320.32KOct 30, 2024
Fidelity Total Market Index Fund0.07%14,7686.26KOct 30, 2024
Fidelity Series Total Market Index Fund0.06%12,3065.22KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.01%3,0481.29KOct 30, 2024
Advertisement